Oscar Health's Investor Day Fails to Dispel Risk-Adjustment Overhang

What happened

Oscar Health hosted an Analyst/Investor Day on September 17, 2026, where management presented its strategic roadmap and reiterated its full-year 2026 guidance of 82.4%–83.4% MLR and $250M–$450M operating income. The event follows a Q1'26 earnings beat that was inflated by a seasonally low 70.5% MLR and $68 million in favorable prior-period reserve development, masking a deteriorating ACA risk-adjustment transfer burden. Q1'26 risk adjustment transfers surged to $1.443 billion, pushing the net risk-adjustment payable to $3.974 billion, and management admitted the accrual ran at ~24% of direct premiums versus the ~20% expected for the full year. Additionally, the expiration of enhanced premium tax credits at end-2025 has already reduced Marketplace participation and Oscar membership, threatening the scale-driven SG&A leverage that underpins profitability. Despite the company's upbeat presentation, the deep value framework assigns a base-case value of $22, a bear-case $14, and rates the stock a potential sell above $27, with the next two quarterly prints serving as critical tests of risk-adjustment normalization.

Implication

The Q1'26 earnings quality is questionable: the 70.5% MLR was 12 percentage points below the full-year guide, and $68 million of favorable reserve development artificially flattered net income; without those tailwinds, quarterly results likely normalize sharply. The risk-adjustment payable build is a structural red flag—if the accrual remains near 24% of direct premiums instead of trending toward 20%, Oscar faces a multi-billion-dollar cash transfer that will pressure capital and earnings for years. Enhanced APTC expiration introduces adverse selection risk, as healthier members drop coverage and sicker members retain it, which could push MLR above 84% and erode the operating leverage story. With the stock at $20.9, the market is pricing in a smooth normalization, but the base-case fair value of $22 and bear-case $14 leave little upside for the risk assumed; investors should trim positions above $27 and consider entry only near $16 if Q2/Q3 data show improvement. Key monitoring: Q2'26 risk adjustment accrual, net payable balance, and membership retention—a deterioration in any of these would validate the bear case and justify exiting the position entirely.

Thesis delta

The deep value thesis already held a cautious stance, and the Investor Day transcript likely reiterated management's confidence without addressing the core risk-adjustment normalization path. The master report's 'potential sell' rating remains unchanged because the event provided no new quantitative evidence that the ~24% risk-adjustment accrual will quickly revert to the ~20% full-year expectation. If anything, the lack of concrete remediation details reinforces the bearish skew, keeping the thesis intact rather than shifting it.